mProX™ Human CD24 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- CD Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human CD24 Stable Cell Line (S01YF-1023-PY226). Click the button above to contact us or submit your feedback about this product.
Morgan Williams (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Casey Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 A decrease in cell proliferation and an augmentation in apoptosis are achieved through the silencing of CD24.
The tumor cell lines under investigation were subjected to a 96-hour treatment with siRNA targeting CD24, while GFP was utilized as a control. Subsequently, antibodies targeting CD24 (SWA11) were applied, followed by PE-conjugated goat anti-mouse IgG, and the cells were subjected to FACS analysis. Western-blot analysis was conducted on whole-cell lysates using SWA11, along with peroxidase-coupled secondary IgG. An MTT proliferation assay was performed on cells subsequent to siCD24 knock-down, with proliferation assessed at the designated time intervals. The induction of apoptosis was examined 72 hours following siCD24 transfection, utilizing PI- and Annexin-V staining.
Ref: Bretz, Niko P., et al. "CD24 controls Src/STAT3 activity in human tumors." Cellular and Molecular Life Sciences 69 (2012): 3863-3879.
Pubmed: 22760497
DOI: 10.1007/s00018-012-1055-9
Research Highlights
Li, Song. et al. "IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy." Antibody therapeutics, 2023.
This study examines the anti-tumor mechanism of IMM47, a humanized anti-CD24 monoclonal antibody (mAb). Techniques including biolayer interferometry, ELISA, and flow cytometry were employed to assess the binding, affinity, and various activities of IMM47 such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular toxicity (ADCT), and complement-dependent cytotoxicity (CDC). The results of this evaluation provide a comprehensive understanding of the effects of IMM47 on tumor cells.
Li, Song. et al. "IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy." Antibody therapeutics, 2023.
Pubmed:
37846296
DOI:
10.1093/abt/tbad020
Azis Suhana, Panaparambil. et al. "Immunological Responses of Arsenicum album 30CH to Combat COVID-19: Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial in the Pathanamthitta District of Kerala." JMIR research protocols, 2023.
COVID-19 is a global crisis that emerged in 2019 and continues to be a major public health concern. It is caused by the SARS-CoV-2 virus and has resulted in approximately 44.6 million confirmed cases and 530,000 deaths in India as of February 1, 2023. In response, the Indian government launched a COVID-19 vaccination campaign in January 2021. However, there is still a lack of an effective and safe preventive strategy with high efficacy and immunological safety.
Azis Suhana, Panaparambil. et al. "Immunological Responses of Arsenicum album 30CH to Combat COVID-19: Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial in the Pathanamthitta District of Kerala." JMIR research protocols, 2023.
Pubmed:
37843912
DOI:
10.2196/48479
